Kempen on Thursday upgraded Belgian biopharmaceutical company UCB (UCB.BR) to buy from neutral and increased its price target to 340 euros from 245 euros.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)